December 3, 2019
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals for Anticipated Launch of ATI-1501 Antibiotic Candidate in the U.S.
December 2, 2019
Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer
November 27, 2019
Appili Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2020
November 21, 2019
Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical
November 18, 2019
Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference
September 26, 2019
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
September 16, 2019
Appili Therapeutics Retains BND Projects for Strategic Investor Relations Services
August 21, 2019
Appili Therapeutics Reports Financial Results for First Quarter of Fiscal Year 2020
August 20, 2019
Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium
July 3, 2019
Appili Therapeutics Announces FY 2019 Financial Results
July 2, 2019
Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs
June 24, 2019
Appili Therapeutics Common Shares to Begin Trading on June 25, 2019 on the TSXV Under the Stock Symbol “APLI”
June 13, 2019
Appili Therapeutics Announces Filing of Final Prospectus 
April 10, 2019
Appili Therapeutics Receives Government of Canada Assistance to Support Continued Growth of its Novel Anti-Infective Pipeline
April 8, 2019
Appili Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference
March 25, 2019
Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus